S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
pixel
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
pixel
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
pixel
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
pixel
pixel

Medical Stocks

This page shows information about the 100 largest medical stocks including Johnson & Johnson, UnitedHealth Group and Novo Nordisk A/S.

Johnson & Johnson logo

#1 - Johnson & Johnson

NYSE:JNJ
Stock Price: $163.72 (+$0.32)
PE Ratio: 24.62
Market Cap: $430.99 billion
P/E Ratio: 24.6
Dividend Yield: 2.59 %
Consensus Rating: Buy (6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $189.75 (15.9% Upside)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
UnitedHealth Group logo

#2 - UnitedHealth Group

NYSE:UNH
Stock Price: $449.16 (+$6.88)
PE Ratio: 29.67
Market Cap: $423.52 billion
P/E Ratio: 29.7
Dividend Yield: 1.29 %
Consensus Rating: Buy (22 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $468.17 (4.2% Upside)
UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health services business serving the broad health care marketplace, including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the health care industry. The OptumRx segment provides pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Minnetonka, MN.
Novo Nordisk A/S logo

#3 - Novo Nordisk A/S

NYSE:NVO
Stock Price: $106.01 (+$1.60)
PE Ratio: 34.64
Market Cap: $249.63 billion
P/E Ratio: 34.6
Dividend Yield: 0.73 %
Consensus Rating: Hold (7 Buy Ratings, 3 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: N/A
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
Pfizer logo

#4 - Pfizer

NYSE:PFE
Stock Price: $43.16 (+$0.30)
PE Ratio: 18.52
Market Cap: $241.98 billion
P/E Ratio: 18.5
Dividend Yield: 3.61 %
Consensus Rating: Hold (2 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $44.00 (1.9% Upside)
Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Thermo Fisher Scientific logo

#5 - Thermo Fisher Scientific

NYSE:TMO
Stock Price: $611.96 (+$3.55)
PE Ratio: 28.37
Market Cap: $240.76 billion
P/E Ratio: 28.4
Dividend Yield: 0.17 %
Consensus Rating: Buy (17 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $615.56 (0.6% Upside)
Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines, as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory on the production line and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare setting
Eli Lilly and logo

#6 - Eli Lilly and

NYSE:LLY
Stock Price: $243.75 (+$2.58)
PE Ratio: 36.54
Market Cap: $233.76 billion
P/E Ratio: 36.5
Dividend Yield: 1.39 %
Consensus Rating: Buy (16 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $259.06 (6.3% Upside)
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo.The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.
Abbott Laboratories logo

#7 - Abbott Laboratories

NYSE:ABT
Stock Price: $126.72 (+$1.67)
PE Ratio: 35.70
Market Cap: $224.65 billion
P/E Ratio: 35.7
Dividend Yield: 1.42 %
Consensus Rating: Buy (9 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $134.57 (6.2% Upside)
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Merck & Co., Inc. logo

#8 - Merck & Co., Inc.

NYSE:MRK
Stock Price: $81.15 (-$0.02)
PE Ratio: 37.05
Market Cap: $205.42 billion
P/E Ratio: 37.1
Dividend Yield: 3.20 %
Consensus Rating: Buy (8 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $93.42 (15.1% Upside)
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
AbbVie logo

#9 - AbbVie

NYSE:ABBV
Stock Price: $109.14 (+$0.38)
PE Ratio: 29.42
Market Cap: $192.87 billion
P/E Ratio: 29.4
Dividend Yield: 4.76 %
Consensus Rating: Buy (12 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $126.67 (16.1% Upside)
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
AstraZeneca logo

#10 - AstraZeneca

NASDAQ:AZN
Stock Price: $61.79 (+$0.57)
PE Ratio: 42.91
Market Cap: $191.44 billion
P/E Ratio: 42.9
Dividend Yield: 2.22 %
Consensus Rating: Buy (11 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $124.00 (100.7% Upside)
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Novartis logo

#11 - Novartis

NYSE:NVS
Stock Price: $84.92 (+$0.25)
PE Ratio: 21.50
Market Cap: $189.94 billion
P/E Ratio: 21.5
Dividend Yield: 2.45 %
Consensus Rating: Hold (5 Buy Ratings, 3 Hold Ratings, 3 Sell Ratings)
Consensus Price Target: $108.50 (27.8% Upside)
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Medtronic logo

#12 - Medtronic

NYSE:MDT
Stock Price: $123.09 (+$1.44)
PE Ratio: 43.04
Market Cap: $165.42 billion
P/E Ratio: 43.0
Dividend Yield: 2.05 %
Consensus Rating: Buy (15 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $144.20 (17.2% Upside)
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consists of products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Minimally Invasive Technologies Group segment focuses on respiratory system, gastrointestinal tract, renal system, lungs, pelvic region, kidneys, and obesity diseases. The Restorative Therapies Group segment comprises of neurostimulation therapies and drug delivery systems for the treatment of chronic pain, as well as areas of the spine and brain, along with pelvic health and conditions of the ear, nose, and throat. The Diabetes Group segment offers insulin pumps, coninuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Moderna logo

#13 - Moderna

NASDAQ:MRNA
Stock Price: $326.54 (-$13.03)
PE Ratio: 40.72
Market Cap: $131.81 billion
P/E Ratio: 40.7
Consensus Rating: Hold (6 Buy Ratings, 6 Hold Ratings, 4 Sell Ratings)
Consensus Price Target: $199.50 (-38.9% Upside)
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Bristol-Myers Squibb logo

#14 - Bristol-Myers Squibb

NYSE:BMY
Stock Price: $57.60 (-$0.21)
PE Ratio: -25.37
Market Cap: $127.99 billion
Dividend Yield: 3.40 %
Consensus Rating: Buy (7 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $72.25 (25.4% Upside)
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
Sanofi logo

#15 - Sanofi

NASDAQ:SNY
Stock Price: $49.92 (+$0.71)
PE Ratio: 18.15
Market Cap: $125.88 billion
P/E Ratio: 18.2
Dividend Yield: 2.74 %
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: N/A
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Intuitive Surgical logo

#16 - Intuitive Surgical

NASDAQ:ISRG
Stock Price: $341.52 (+$1.89)
PE Ratio: 25.52
Market Cap: $121.91 billion
P/E Ratio: 25.5
Consensus Rating: Hold (6 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $335.40 (-1.8% Upside)
Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.
Amgen logo

#17 - Amgen

NASDAQ:AMGN
Stock Price: $209.24 (+$0.25)
PE Ratio: 21.29
Market Cap: $118.82 billion
P/E Ratio: 21.3
Dividend Yield: 3.36 %
Consensus Rating: Hold (9 Buy Ratings, 9 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $244.00 (16.6% Upside)
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
GlaxoSmithKline logo

#18 - GlaxoSmithKline

NYSE:GSK
Stock Price: $39.77 (+$0.22)
PE Ratio: 16.78
Market Cap: $107.08 billion
P/E Ratio: 16.8
Dividend Yield: 5.13 %
Consensus Rating: Hold (4 Buy Ratings, 5 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: N/A
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Anthem logo

#19 - Anthem

NYSE:ANTM
Stock Price: $433.34 (+$2.93)
PE Ratio: 25.46
Market Cap: $105.65 billion
P/E Ratio: 25.5
Dividend Yield: 1.04 %
Consensus Rating: Buy (18 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $447.14 (3.2% Upside)
Anthem, Inc. provides life, hospital and medical insurance plans. It offers a broad spectrum of network-based managed care health benefit plans to the large and small employer, individual, Medicaid, and Medicare markets. The company operates through the following segments: Commercial & Specialty Business, Government Business, IngenioRx and Other. The Commercial and Specialty Business segment includes local group, national accounts, individual and specialty businesses. The Government Business segment includes medicare and medicaid businesses, national government services and services provided to the federal government in connection with federal employee program. The IngenioRx Business segment includes PBM services to affiliated health plan customers, as well as to external customers outside of the health plans. The Other segment includes Diversified Business Group (“DBG“), which is integrated health services business. Anthem was founded on November 30, 2004 and is headquartered in Indianapolis, IN.
Stryker logo

#20 - Stryker

NYSE:SYK
Stock Price: $275.73 (-$0.71)
PE Ratio: 50.50
Market Cap: $103.98 billion
P/E Ratio: 50.5
Dividend Yield: 0.91 %
Consensus Rating: Buy (14 Buy Ratings, 7 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $286.43 (3.9% Upside)
Stryker Corp. engages in the provision of medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg, and Neurotechnology & Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The MedSurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling and reprocessed medical devices. The Neurotechnology & Spine segment pertains to spinal implants and neurovascular products. The company was founded by Homer H. Stryker in 1941 and is headquartered in Kalamazoo, MI.
Zoetis logo

#21 - Zoetis

NYSE:ZTS
Stock Price: $208.51 (-$0.11)
PE Ratio: 52.26
Market Cap: $98.82 billion
P/E Ratio: 52.3
Dividend Yield: 0.48 %
Consensus Rating: Buy (5 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $203.11 (-2.6% Upside)
Zoetis, Inc. discovers, develops, and manufactures a portfolio of animal health medicines and vaccines. The firm operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices, and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The company provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals. Zoetis was founded in 1952 and is headquartered in Parsippany, NJ.
Gilead Sciences logo

#22 - Gilead Sciences

NASDAQ:GILD
Stock Price: $67.24 (+$0.25)
PE Ratio: 16.40
Market Cap: $84.31 billion
P/E Ratio: 16.4
Dividend Yield: 4.22 %
Consensus Rating: Buy (10 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $109.94 (63.5% Upside)
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
HCA Healthcare logo

#23 - HCA Healthcare

NYSE:HCA
Stock Price: $253.11 (-$6.89)
PE Ratio: 17.36
Market Cap: $81.03 billion
P/E Ratio: 17.4
Dividend Yield: 0.76 %
Consensus Rating: Buy (17 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $258.47 (2.1% Upside)
HCA Healthcare, Inc. is a health care services company, which engages in operating hospitals, freestanding surgery centers and emergency rooms, and urgent care centers. It offers a full range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. The company was founded by Dr. Thomas Frist, Sr., Dr. Thomas Frist, Jr., and Jack Massey in 1968 and is headquartered in Nashville, TN.
Edwards Lifesciences logo

#24 - Edwards Lifesciences

NYSE:EW
Stock Price: $116.59 (+$0.85)
PE Ratio: 50.04
Market Cap: $72.67 billion
P/E Ratio: 50.0
Consensus Rating: Buy (12 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $118.44 (1.6% Upside)
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
Becton, Dickinson and logo

#25 - Becton, Dickinson and

NYSE:BDX
Stock Price: $247.09 (+$0.62)
PE Ratio: 38.79
Market Cap: $70.96 billion
P/E Ratio: 38.8
Dividend Yield: 1.34 %
Consensus Rating: Hold (4 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $273.63 (10.7% Upside)
Becton, Dickinson & Co. is a medical technology company. The firm engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens; and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.
Aetna logo

#26 - Aetna

NYSE:AET
Stock Price: $212.70
PE Ratio: 21.57
Market Cap: $69.64 billion
P/E Ratio: 21.6
Dividend Yield: 0.94 %
Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis. It also provides point-of-service, preferred provider organization, health maintenance organization, and indemnity benefit plans, as well as health savings accounts and consumer-directed health plans. In addition, this segment offers Medicare and Medicaid products and services, as well as other medical products, such as medical management and data analytics services, medical stop loss insurance, workers' compensation administrative services, and products that provide access to its provider networks in select geographies. The Group Insurance segment offers life insurance products, including group term life insurance, voluntary spouse and dependent term life insurance, group universal life insurance, and accidental death and dismemberment insurance; disability insurance products; and long-term care insurance products, which provide the benefits to cover the cost of care in private home settings, adult day care, assisted living, or nursing facilities. The Large Case Pensions segment manages various retirement products comprising pension and annuity products primarily for tax-qualified pension plans. The company provides its products and services to employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Aetna Inc. was founded in 1853 and is based in Hartford, Connecticut.
BioNTech logo

#27 - BioNTech

NASDAQ:BNTX
Stock Price: $278.34 (-$8.02)
PE Ratio: 14.57
Market Cap: $67.50 billion
P/E Ratio: 14.6
Consensus Rating: Hold (5 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $253.79 (-8.8% Upside)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Boston Scientific logo

#28 - Boston Scientific

NYSE:BSX
Stock Price: $44.84 (-$0.03)
PE Ratio: 135.88
Market Cap: $63.85 billion
P/E Ratio: 135.9
Consensus Rating: Buy (11 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $49.13 (9.6% Upside)
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.
Allergan logo

#29 - Allergan

NYSE:AGN
Stock Price: $0.00
PE Ratio: -12.07
Market Cap: $63.50 billion
Dividend Yield: 1.53 %
Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Regeneron Pharmaceuticals logo

#30 - Regeneron Pharmaceuticals

NASDAQ:REGN
Stock Price: $572.36 (+$2.99)
PE Ratio: 10.28
Market Cap: $61.22 billion
P/E Ratio: 10.3
Consensus Rating: Buy (13 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $699.19 (22.2% Upside)
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
Illumina logo

#31 - Illumina

NASDAQ:ILMN
Stock Price: $409.15 (-$2.43)
PE Ratio: 78.38
Market Cap: $60.02 billion
P/E Ratio: 78.4
Consensus Rating: Hold (5 Buy Ratings, 3 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $435.00 (6.3% Upside)
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Humana logo

#32 - Humana

NYSE:HUM
Stock Price: $461.85 (+$1.04)
PE Ratio: 24.41
Market Cap: $59.35 billion
P/E Ratio: 24.4
Dividend Yield: 0.61 %
Consensus Rating: Buy (11 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $485.18 (5.1% Upside)
Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental benefit plans such as Medicare, and State-based Medicaid contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance benefits. The Healthcare Services segment offer services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics services to other Humana businesses, as well as external health plan members, external health plans, and other employers. The company was founded by David A. Jones, Sr. and Wendell Cherry in 1961 and is headquartered in Louisville, KY.
IDEXX Laboratories logo

#33 - IDEXX Laboratories

NASDAQ:IDXX
Stock Price: $651.85 (+$6.61)
PE Ratio: 77.69
Market Cap: $55.46 billion
P/E Ratio: 77.7
Consensus Rating: Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $675.00 (3.6% Upside)
IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. The Water segment develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. The LPD segment develops, designs, manufactures, and distributes diagnostic tests and related instrumentation and performs services, which are used to manage the health status of livestock and poultry, to improve producer, and to ensure the quality and safety of milk and food. The Other operating segment combines and presents products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.
DexCom logo

#34 - DexCom

NASDAQ:DXCM
Stock Price: $566.57 (-$1.53)
PE Ratio: 107.92
Market Cap: $54.82 billion
P/E Ratio: 107.9
Consensus Rating: Buy (13 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $516.93 (-8.8% Upside)
DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.
Shire logo

#35 - Shire

NASDAQ:SHPG
Stock Price: $179.20
PE Ratio: 11.83
Market Cap: $54.71 billion
P/E Ratio: 11.8
Dividend Yield: 0.19 %
Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.
Express Scripts logo

#36 - Express Scripts

NASDAQ:ESRX
Stock Price: $92.33
PE Ratio: 13.00
Market Cap: $52.06 billion
P/E Ratio: 13.0
Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.
Vertex Pharmaceuticals logo

#37 - Vertex Pharmaceuticals

NASDAQ:VRTX
Stock Price: $183.52 (-$3.57)
PE Ratio: 24.21
Market Cap: $47.61 billion
P/E Ratio: 24.2
Consensus Rating: Buy (16 Buy Ratings, 4 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $266.61 (45.3% Upside)
Vertex Pharmaceuticals, Inc. is a global biotechnology company. It engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Align Technology logo

#38 - Align Technology

NASDAQ:ALGN
Stock Price: $590.56 (-$8.93)
PE Ratio: 67.26
Market Cap: $46.66 billion
P/E Ratio: 67.3
Consensus Rating: Buy (12 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $708.75 (20.0% Upside)
Align Technology, Inc. engages in the design, manufacture, and market of orthodontics, restorative, and aesthetic dentistry products. It operates through the Clear Aligner, and Scanner and Services segments. The Clear Aligner segment consists of invisalign full, teen, and assist products, and vivera retainers for treating malocclusion. The Scanner and Services segment comprises of intraoral scanning systems such as single hardware platforms and restorative or orthodontic software options, ancillary products, and other related additional services. The company was founded by Zia Chishti, Brian Freyburger, and Kelsey Wirth in March 1997 and is headquartered in Tempe, AZ.
Takeda Pharmaceutical logo

#39 - Takeda Pharmaceutical

NYSE:TAK
Stock Price: $14.07 (+$0.05)
PE Ratio: 9.64
Market Cap: $44.52 billion
P/E Ratio: 9.6
Dividend Yield: 4.83 %
Consensus Rating: Hold (0 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
DiDi Global logo

#40 - DiDi Global

NYSE:DIDI
Stock Price: $9.19 (-0.62)
Market Cap: $44.33 billion
Consensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: 25.00 (172.0% Upside)
DiDi Global Inc., a mobility technology platform, provides ride hailing and other services in the People's Republic of China, Brazil, Mexico, and internationally. It offers ride hailing, taxi hailing, chauffeur, hitch, and other forms of shared mobility services, as well as enterprise business ride solutions; auto solutions comprising leasing, refueling, and maintenance and repair services; electric vehicle leasing services; bike and e-bike sharing, intra-city freight, food delivery, and financial services. The company was formerly known as Xiaoju Kuaizhi Inc. and changed its name to DiDi Global Inc. in June 2021. DiDi Global Inc. was founded in 2012 and is headquartered in Beijing, China.
Koninklijke Philips logo

#41 - Koninklijke Philips

NYSE:PHG
Stock Price: $48.07 (+$0.57)
PE Ratio: 36.42
Market Cap: $43.52 billion
P/E Ratio: 36.4
Dividend Yield: 1.83 %
Consensus Rating: Buy (7 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Personal Health, Diagnosis & Treatment, Connected Care & Health Informatics, and Other. The Personal Health segment focuses on healthy living and preventative care. This segment comprises the Personal Care, Domestic Appliances, Oral Healthcare, and Mother & Child Care businesses. The Diagnosis & Treatment segment unites the businesses related to the promise of precision diagnosis and disease pathway selection, and the businesses related to image-guided, minimally invasive treatments. This segment comprises the Diagnostic Imaging, Ultrasound, Healthcare Informatics and Image-Guided Therapy businesses. The Connected Care & Health Informatics segment focuses on patient care solutions, advanced analytics and patient and workflow optimization inside and outside the hospital, and aims to unlock synergies from integrating and optimizing patient care pathways and leveraging provider-payer-patient business models. This segment comprises the Monitoring & Analytics, Therapeutic Care, Population Health Management, and Sleep & Re
Baxter International logo

#42 - Baxter International

NYSE:BAX
Stock Price: $82.19 (+$0.73)
PE Ratio: 37.53
Market Cap: $41.09 billion
P/E Ratio: 37.5
Dividend Yield: 1.36 %
Consensus Rating: Buy (8 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $91.18 (10.9% Upside)
Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
Centene logo

#43 - Centene

NYSE:CNC
Stock Price: $69.24 (+$0.25)
PE Ratio: 56.75
Market Cap: $40.37 billion
P/E Ratio: 56.8
Consensus Rating: Buy (15 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $82.81 (19.6% Upside)
Centene Corp. operates as a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Managed Care and Specialty Services. The Medicaid Managed Care segment provides health plan coverage to individuals through government subsidized programs through Medicaid. The Specialty Services segment offers healthcare services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company was founded in 1984 and is headquartered in St. Louis, MO.
Alexion Pharmaceuticals logo

#44 - Alexion Pharmaceuticals

NASDAQ:ALXN
Stock Price: $182.50
PE Ratio: 59.64
Market Cap: $40.34 billion
P/E Ratio: 59.6
Consensus Rating: Hold (3 Buy Ratings, 12 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $161.93 (-11.3% Upside)
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Alcon logo

#45 - Alcon

NYSE:ALC
Stock Price: $81.91 (+$0.37)
PE Ratio: 221.38
Market Cap: $39.99 billion
P/E Ratio: 221.4
Consensus Rating: Buy (9 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $85.20 (4.0% Upside)
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Fribourg, Switzerland.
Biogen logo

#46 - Biogen

NASDAQ:BIIB
Stock Price: $264.80 (-$5.41)
PE Ratio: 21.25
Market Cap: $39.46 billion
P/E Ratio: 21.3
Consensus Rating: Buy (17 Buy Ratings, 13 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $379.39 (43.3% Upside)
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
ResMed logo

#47 - ResMed

NYSE:RMD
Stock Price: $267.50 (+$4.46)
PE Ratio: 82.56
Market Cap: $38.97 billion
P/E Ratio: 82.6
Dividend Yield: 0.63 %
Consensus Rating: Hold (5 Buy Ratings, 5 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $241.50 (-9.7% Upside)
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the following segments: Sleep and Respiratory Care, and Software as a Service. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment engages in the supply of business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.
BeiGene logo

#48 - BeiGene

NASDAQ:BGNE
Stock Price: $378.88 (+$3.60)
PE Ratio: -26.04
Market Cap: $35.36 billion
Consensus Rating: Buy (8 Buy Ratings, 1 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $356.88 (-5.8% Upside)
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.
McKesson logo

#49 - McKesson

NYSE:MCK
Stock Price: $209.09 (+$1.90)
PE Ratio: -7.40
Market Cap: $32.34 billion
Dividend Yield: 0.90 %
Consensus Rating: Buy (6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $224.13 (7.2% Upside)
McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical; International; Medical-Surgical Solutions; and Prescription Technology Solutions (“RxTS“). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices; and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS
Zimmer Biomet logo

#50 - Zimmer Biomet

NYSE:ZBH
Stock Price: $150.42 (-$0.39)
PE Ratio: 34.50
Market Cap: $31.41 billion
P/E Ratio: 34.5
Dividend Yield: 0.64 %
Consensus Rating: Buy (17 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $179.95 (19.6% Upside)
Zimmer Biomet Holdings, Inc. provides musculoskeletal healthcare services. It operates through the following segments: Americas and Global Businesses, EMEA, and Asia Pacific. The Americas and Global Businesses segment consists of U.S. and includes other North, Central and South American markets for all product categories as well as the global results for the Dental products division. The EMEA segment focuses in Europe and includes the Middle East and African markets for all product categories except Dental. The Asia Pacific segment comprises of Japan, China and Australia and includes other Asian and Pacific markets for all product categories except Dental. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
Seagen logo

#51 - Seagen

NASDAQ:SGEN
Stock Price: $171.43 (-$2.47)
PE Ratio: 52.59
Market Cap: $31.19 billion
P/E Ratio: 52.6
Consensus Rating: Buy (6 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $178.44 (4.1% Upside)
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
West Pharmaceutical Services logo

#52 - West Pharmaceutical Services

NYSE:WST
Stock Price: $421.19 (-$1.04)
PE Ratio: 61.58
Market Cap: $31.16 billion
P/E Ratio: 61.6
Dividend Yield: 0.16 %
Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $475.00 (12.8% Upside)
West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.
Genmab A/S logo

#53 - Genmab A/S

NASDAQ:GMAB
Stock Price: $46.73 (+$0.34)
PE Ratio: 75.37
Market Cap: $30.69 billion
P/E Ratio: 75.4
Consensus Rating: Hold (6 Buy Ratings, 5 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $44.71 (-4.3% Upside)
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.
Laboratory Co. of America logo

#54 - Laboratory Co. of America

NYSE:LH
Stock Price: $282.15 (+$2.34)
PE Ratio: 9.63
Market Cap: $27.20 billion
P/E Ratio: 9.6
Consensus Rating: Buy (13 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $316.57 (12.2% Upside)
Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.
Horizon Therapeutics Public logo

#55 - Horizon Therapeutics Public

NASDAQ:HZNP
Stock Price: $116.45 (-$0.01)
PE Ratio: 51.76
Market Cap: $26.31 billion
P/E Ratio: 51.8
Consensus Rating: Buy (8 Buy Ratings, 1 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $119.89 (3.0% Upside)
Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.
AmerisourceBergen logo

#56 - AmerisourceBergen

NYSE:ABC
Stock Price: $123.32 (+$0.61)
PE Ratio: -6.69
Market Cap: $25.62 billion
Dividend Yield: 1.43 %
Consensus Rating: Buy (6 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $137.00 (11.1% Upside)
AmerisourceBergen Corp. engages provision of pharmaceutical products and business solutions that improve access to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical Distribution Services segment distributes an offering of brand-name; specialty brand-name and generic pharmaceuticals; over-the-counter healthcare products; home healthcare supplies and equipment; and related services to healthcare providers, including acute care hospitals and health systems; independent and chain retail pharmacies; mail order pharmacies; medical clinics; and long-term care and alternate site pharmacies. The Other segment focuses on global commercialization services and animal health; and includes AmerisourceBergen Consulting Services ABCS, World Courier, and MWI. The company was founded in 1947 and is headquartered in Conshohocken, PA.
Alnylam Pharmaceuticals logo

#57 - Alnylam Pharmaceuticals

NASDAQ:ALNY
Stock Price: $198.61 (-$5.72)
PE Ratio: -26.17
Market Cap: $23.60 billion
Consensus Rating: Buy (7 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $177.31 (-10.7% Upside)
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm's products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
STERIS logo

#58 - STERIS

NYSE:STE
Stock Price: $235.31 (+$3.03)
PE Ratio: 70.45
Market Cap: $23.47 billion
P/E Ratio: 70.5
Dividend Yield: 0.73 %
Consensus Rating: Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $242.40 (3.0% Upside)
STERIS Plc engages in the provision of healthcare and life science product and service solutions. It operates through the following segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers portfolio of infection prevention, procedural, and gastrointestinal solutions. The Healthcare Specialty Services segment delivers solutions and managed services including hospital sterilization services and instrument, and scope repairs to acute care hospitals and other healthcare settings. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capitalequipment. The Applied Sterilization Technologies segment involves in contract sterilization and testing services for medical device and pharmaceutical manufacturer. The company was founded in 1985 and is headquartered in Dublin, Ireland.
Catalent logo

#59 - Catalent

NYSE:CTLT
Stock Price: $132.73 (+$0.42)
PE Ratio: 42.95
Market Cap: $22.67 billion
P/E Ratio: 43.0
Consensus Rating: Buy (9 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $140.80 (6.1% Upside)
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets, and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy; formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges; and analytical development and testing services for large molecules. The Oral and Speciality Delivery segment consists of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment involves packaging, storage, distribution, and inventory management f
Avantor logo

#60 - Avantor

NYSE:AVTR
Stock Price: $38.42 (-$0.35)
PE Ratio: 85.38
Market Cap: $22.44 billion
P/E Ratio: 85.4
Consensus Rating: Buy (15 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $43.69 (13.7% Upside)
Avantor, Inc. is a provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. It sells materials & consumables, equipment & instrumentation and services & specialty procurement. It operates through the following segments: the Americas, Europe, and AMEA. The company was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.
Bio-Rad Laboratories logo

#61 - Bio-Rad Laboratories

NYSE:BIO
Stock Price: $753.58 (-$6.27)
PE Ratio: 5.62
Market Cap: $22.44 billion
P/E Ratio: 5.6
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $770.00 (2.2% Upside)
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
Teladoc Health logo

#62 - Teladoc Health

NYSE:TDOC
Stock Price: $137.79 (-$2.74)
PE Ratio: -24.30
Market Cap: $21.94 billion
Consensus Rating: Buy (13 Buy Ratings, 10 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $217.00 (57.5% Upside)
Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002 by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.
Bio-Rad Laboratories logo

#63 - Bio-Rad Laboratories

NYSE:BIO.B
Stock Price: $729.86
PE Ratio: 5.44
Market Cap: $21.73 billion
P/E Ratio: 5.4
Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Cerner logo

#64 - Cerner

NASDAQ:CERN
Stock Price: $71.81 (-$0.06)
PE Ratio: 31.36
Market Cap: $21.23 billion
P/E Ratio: 31.4
Dividend Yield: 1.23 %
Consensus Rating: Buy (7 Buy Ratings, 1 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $84.40 (17.5% Upside)
Cerner Corp. designs, develops, markets, installs, hosts and supports health care information technology, health care devices, hardware and content solutions for health care organizations and consumers. The company also provides value-added services, including implementation and training, remote hosting, operational management services, revenue cycle services, support and maintenance, health care data analysis, clinical process optimization, transaction processing, employee wellness programs and third party administrator services for employer-based health plans. It operates through the following segments: Domestic and International. The Domestic segment includes revenue contributions and expenditures associated with business activity in the United States. The International segment includes revenue contributions and expenditures linked to business activity in Aruba, Australia, Austria, the Bahamas, Belgium, Bermuda, Brazil, Canada, Cayman Islands, Chile, Denmark, Egypt, England, Finland, France, Germany, Guam, India, Ireland, Kuwait, Luxembourg, Malaysia, Mexico, Netherlands, Norway, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovakia, Spain, Sweden, Switzerland and the Unit
Charles River Laboratories International logo

#65 - Charles River Laboratories International

NYSE:CRL
Stock Price: $420.61 (+$3.40)
PE Ratio: 54.20
Market Cap: $21.20 billion
P/E Ratio: 54.2
Consensus Rating: Buy (10 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $399.83 (-4.9% Upside)
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client's use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
Insulet logo

#66 - Insulet

NASDAQ:PODD
Stock Price: $304.33 (+$0.98)
PE Ratio: -661.59
Market Cap: $20.96 billion
Consensus Rating: Buy (7 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $283.50 (-6.8% Upside)
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
Fresenius Medical Care AG & Co. KGaA logo

#67 - Fresenius Medical Care AG & Co. KGaA

NYSE:FMS
Stock Price: $35.62 (-$0.43)
PE Ratio: 17.55
Market Cap: $20.87 billion
P/E Ratio: 17.5
Dividend Yield: 1.60 %
Consensus Rating: Hold (5 Buy Ratings, 12 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $40.00 (12.3% Upside)
Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.
The Cooper Companies logo

#68 - The Cooper Companies

NYSE:COO
Stock Price: $417.02 (+$5.46)
PE Ratio: 7.11
Market Cap: $20.56 billion
P/E Ratio: 7.1
Dividend Yield: 0.01 %
Consensus Rating: Buy (9 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $443.73 (6.4% Upside)
The Cooper Cos, Inc. operates as a medical device company. It operates through the Cooper Vision and Cooper Surgical segments. The Cooper Vision segment develops, manufactures, and markets products for contact lens wearers, which solves vision challenges such as astigmatism, presbyopia, myopia, ocular dryness, and eye fatigues. The Cooper Surgical segment focuses on the provision of advancement for the health of women, basies, and families through women's health and fertility products and services. The company was founded in 1958 and is headquartered in San Ramon, CA.
Immunomedics logo

#69 - Immunomedics

NASDAQ:IMMU
Stock Price: $87.86
PE Ratio: -50.79
Market Cap: $20.31 billion
Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.
Bio-Techne logo

#70 - Bio-Techne

NASDAQ:TECH
Stock Price: $505.26 (+$7.81)
PE Ratio: 145.61
Market Cap: $19.75 billion
P/E Ratio: 145.6
Dividend Yield: 0.25 %
Consensus Rating: Buy (7 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $458.00 (-9.4% Upside)
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The co
Hologic logo

#71 - Hologic

NASDAQ:HOLX
Stock Price: $73.61 (-$0.03)
PE Ratio: 9.44
Market Cap: $18.66 billion
P/E Ratio: 9.4
Consensus Rating: Buy (9 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $86.93 (18.1% Upside)
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment comprises products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.
GoodRx logo

#72 - GoodRx

NASDAQ:GDRX
Stock Price: $47.16 (+$0.16)
PE Ratio: -53.59
Market Cap: $18.66 billion
Consensus Rating: Buy (8 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $46.69 (-1.0% Upside)
GoodRx Holdings, Inc., through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including telehealth services. The company serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is based in Santa Monica, California.
10x Genomics logo

#73 - 10x Genomics

NASDAQ:TXG
Stock Price: $164.03 (+$0.18)
PE Ratio: -34.68
Market Cap: $18.19 billion
Consensus Rating: Buy (5 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $172.38 (5.1% Upside)
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Quest Diagnostics logo

#74 - Quest Diagnostics

NYSE:DGX
Stock Price: $146.49 (+$1.13)
PE Ratio: 8.74
Market Cap: $17.90 billion
P/E Ratio: 8.7
Dividend Yield: 1.69 %
Consensus Rating: Buy (6 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $160.56 (9.6% Upside)
Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.
Teleflex logo

#75 - Teleflex

NYSE:TFX
Stock Price: $376.51 (-$1.77)
PE Ratio: 50.81
Market Cap: $17.62 billion
P/E Ratio: 50.8
Dividend Yield: 0.36 %
Consensus Rating: Buy (9 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $455.80 (21.1% Upside)
Teleflex, Inc. provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The firm designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.
WellCare Health Plans logo

#76 - WellCare Health Plans

NYSE:WCG
Stock Price: $0.00
PE Ratio: 28.15
Market Cap: $17.61 billion
P/E Ratio: 28.2
Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
WellCare Health Plans, Inc. provides government-sponsored managed care services. The company operates in three segments: Medicaid Health Plans, Medicare Health Plans, and Medicare Prescription Drug Plans (PDPs). The Medicaid Health Plans segment offers plans for beneficiaries of temporary assistance for needy families, supplemental security income, and aged blind and disabled residents; and other state-based programs, such as children's health insurance programs and long-term services and supports programs for qualifying families who are not eligible for Medicaid. The Medicare Health Plans segment provides Medicare, a federal program that provides eligible persons aged 65 and over, as well as some disabled persons with a range of hospital, medical, and prescription drug benefits; Medicare Advantage, a Medicare's managed care alternative to the original Medicare program, which offers individuals standard Medicare benefits directly through Centers for Medicare & Medicaid Services; and coordinated care plans that are administered through health maintenance organizations and require members to seek health care services and select a primary care physician from a network of health care providers. The Medicare PDPs segment provides Medicare part D PDP plans to Medicare-eligible beneficiaries. Its PDP plans offer national in-network prescription drug coverage, including a preferred pharmacy network. As of December 31, 2018, the company served approximately 5.5 million members in the United States. WellCare Health Plans, Inc. was founded in 1985 and is headquartered in Tampa, Florida.
Molina Healthcare logo

#77 - Molina Healthcare

NYSE:MOH
Stock Price: $297.89 (+$1.64)
PE Ratio: 27.81
Market Cap: $17.40 billion
P/E Ratio: 27.8
Consensus Rating: Buy (10 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $288.66 (-3.1% Upside)
Molina Healthcare, Inc. engages in the provision of health care services. It operates through the Health Plans and Other segments. The Health Plans segment consists of health plans in 11 states and the Commonwealth of Puerto Rico and includes direct delivery business. The Other segment includes the historical results of the MMIS and behavioral health subsidiaries. The company was founded by C. David Molina in 1980 and is headquartered in Long Beach, CA.
Viatris logo

#78 - Viatris

NASDAQ:VTRS
Stock Price: $13.94 (-$0.07)
PE Ratio: -7.74
Market Cap: $16.86 billion
Dividend Yield: 3.16 %
Consensus Rating: Hold (4 Buy Ratings, 9 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $18.44 (32.3% Upside)
Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines, sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.
PPD logo

#79 - PPD

NASDAQ:PPD
Stock Price: $47.03 (-$0.01)
PE Ratio: 65.32
Market Cap: $16.52 billion
P/E Ratio: 65.3
Consensus Rating: Hold (3 Buy Ratings, 10 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $44.93 (-4.5% Upside)
PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.
Varian Medical Systems logo

#80 - Varian Medical Systems

NYSE:VAR
Stock Price: $0.00
PE Ratio: 60.43
Market Cap: $16.26 billion
P/E Ratio: 60.4
Consensus Rating: Hold (0 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $178.00
Varian Medical Systems, Inc. designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide. It operates through Oncology Systems and Proton Solutions segments. The Oncology Systems segment offers hardware and software products for treating cancer with radiotherapy, fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, artificial intelligence based adaptive radiotherapy, and brachytherapy, as well as quality assurance equipment. Its products include linear accelerators, brachytherapy afterloaders, treatment accessories, and quality assurance software; and information management, treatment planning, image processing, clinical knowledge exchange, patient care management, decision-making support, and practice management software. This segment serves university research and community hospitals, private and governmental institutions, healthcare agencies, physicians' offices, medical oncology practices, radiotherapy centers, and cancer care clinics. The Proton Solutions segment designs, develops, manufactures, sells, and services products and systems for delivering proton therapy for the treatment of cancer. The company has a strategic agreement with McKesson Corp. to supply treatment delivery systems and planning, services, and radiotherapy information system solutions to its U.S. Oncology Network and Vantage Oncology affiliated sites of care; and a strategic partnership with Siemens AG to represent Siemens diagnostic imaging products to radiation oncology clinics in the United States and other select markets. Varian Medical Systems, Inc. was formerly known as Varian Associates, Inc. and changed its name to Varian Medical Systems, Inc. in April 1999. The company was founded in 1948 and is headquartered in Palo Alto, California.
Exact Sciences logo

#81 - Exact Sciences

NASDAQ:EXAS
Stock Price: $93.98 (-$2.22)
PE Ratio: -17.21
Market Cap: $16.16 billion
Consensus Rating: Buy (13 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $148.25 (57.7% Upside)
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.
Elanco Animal Health logo

#82 - Elanco Animal Health

NYSE:ELAN
Stock Price: $33.90 (+$0.30)
PE Ratio: -22.60
Market Cap: $16.04 billion
Consensus Rating: Buy (6 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $36.50 (7.7% Upside)
Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food
Abiomed logo

#83 - Abiomed

NASDAQ:ABMD
Stock Price: $352.18 (+$2.50)
PE Ratio: 104.82
Market Cap: $15.98 billion
P/E Ratio: 104.8
Consensus Rating: Hold (2 Buy Ratings, 1 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $363.75 (3.3% Upside)
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA.
Smith & Nephew logo

#84 - Smith & Nephew

NYSE:SNN
Stock Price: $35.67 (-$0.01)
PE Ratio: 27.65
Market Cap: $15.68 billion
P/E Ratio: 27.7
Dividend Yield: 1.57 %
Consensus Rating: Buy (6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $50.75 (42.3% Upside)
Smith & Nephew PLC engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.
Masimo logo

#85 - Masimo

NASDAQ:MASI
Stock Price: $283.35 (+$0.89)
PE Ratio: 73.41
Market Cap: $15.60 billion
P/E Ratio: 73.4
Consensus Rating: Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $292.75 (3.3% Upside)
Masimo Corp. is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.
Repligen logo

#86 - Repligen

NASDAQ:RGEN
Stock Price: $274.95 (+$4.19)
PE Ratio: 153.60
Market Cap: $15.10 billion
P/E Ratio: 153.6
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $306.14 (11.3% Upside)
Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
argenx logo

#87 - argenx

NASDAQ:ARGX
Stock Price: $293.16 (-$1.01)
PE Ratio: -41.94
Market Cap: $15.08 billion
Consensus Rating: Buy (10 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $351.69 (20.0% Upside)
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.
ICON Public logo

#88 - ICON Public

NASDAQ:ICLR
Stock Price: $277.52 (+$0.39)
PE Ratio: 40.69
Market Cap: $14.67 billion
P/E Ratio: 40.7
Consensus Rating: Buy (9 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $260.45 (-6.1% Upside)
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.
Incyte logo

#89 - Incyte

NASDAQ:INCY
Stock Price: $65.79 (-$0.08)
PE Ratio: 43.28
Market Cap: $14.53 billion
P/E Ratio: 43.3
Consensus Rating: Hold (6 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $89.11 (35.4% Upside)
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Livongo Health logo

#90 - Livongo Health

NASDAQ:LVGO
Stock Price: $139.77
PE Ratio: -349.42
Market Cap: $14.20 billion
Consensus Rating: Hold (1 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $149.50 (7.0% Upside)
Livongo Health, Inc. provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications. Its products include Livongo for Diabetes, Livongo for Hypertension, Livongo for Prediabetes and Weight Management, and Livongo for Behavioral Health by myStrength. The company was formerly known as EosHealth, Inc. and changed its name to Livongo Health, Inc. in 2014. Livongo Health, Inc. was incorporated in 2008 and is headquartered in Mountain View, California.
Cardinal Health logo

#91 - Cardinal Health

NYSE:CAH
Stock Price: $49.57 (+$0.51)
PE Ratio: 23.95
Market Cap: $14.07 billion
P/E Ratio: 23.9
Dividend Yield: 3.95 %
Consensus Rating: Hold (1 Buy Ratings, 5 Hold Ratings, 2 Sell Ratings)
Consensus Price Target: $58.50 (18.0% Upside)
Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the following segments: Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes cardinal health branded medical, surgical, and laboratory products. Cardinal Health was founded by Robert D. Walter in 1971 and is headquartered in Dublin, OH.
BioMarin Pharmaceutical logo

#92 - BioMarin Pharmaceutical

NASDAQ:BMRN
Stock Price: $73.74 (-$1.34)
PE Ratio: 17.19
Market Cap: $13.52 billion
P/E Ratio: 17.2
Consensus Rating: Buy (9 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $103.24 (40.0% Upside)
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
DENTSPLY SIRONA logo

#93 - DENTSPLY SIRONA

NASDAQ:XRAY
Stock Price: $58.30 (+$0.02)
PE Ratio: 34.70
Market Cap: $12.74 billion
P/E Ratio: 34.7
Dividend Yield: 0.75 %
Consensus Rating: Hold (3 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $67.50 (15.8% Upside)
Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Technologies and Equipment and Consumables. The Technologies and Equipment segments comprises dental technology, equipment and healthcare consumable products such as dental implants, laboratory dental products, computer-aided design and computer-aided manufacturing systems, imaging systems, treatment centers and consumable medical device products. The Consumables segment offers preventive, restorative, instruments, endodontic and orthodontic dental products. The company was founded in 1899 and is headquartered in Charlotte, NC.
NovoCure logo

#94 - NovoCure

NASDAQ:NVCR
Stock Price: $120.74 (-$1.25)
PE Ratio: -2,414.32
Market Cap: $12.51 billion
Consensus Rating: Hold (2 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $186.14 (54.2% Upside)
NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
QIAGEN logo

#95 - QIAGEN

NYSE:QGEN
Stock Price: $53.99 (+$0.43)
PE Ratio: 26.21
Market Cap: $12.31 billion
P/E Ratio: 26.2
Consensus Rating: Buy (7 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $52.27 (-3.2% Upside)
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
DaVita logo

#96 - DaVita

NYSE:DVA
Stock Price: $115.61 (+$0.20)
PE Ratio: 15.39
Market Cap: $12.12 billion
P/E Ratio: 15.4
Consensus Rating: Hold (1 Buy Ratings, 5 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $144.33 (24.8% Upside)
DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.
Doximity logo

#97 - Doximity

NASDAQ:DOCS
Stock Price: $64.75 (-$3.12)
Market Cap: $12.02 billion
Consensus Rating: Buy (6 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $66.86 (3.3% Upside)
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's cloud-based platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical companies and health systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
MyoKardia logo

#98 - MyoKardia

NASDAQ:MYOK
Stock Price: $224.91
PE Ratio: -39.88
Market Cap: $11.99 billion
Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Oak Street Health logo

#99 - Oak Street Health

NYSE:OSH
Stock Price: $46.92 (+$0.47)
PE Ratio: -36.66
Market Cap: $11.30 billion
Consensus Rating: Buy (15 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $63.75 (35.9% Upside)
Oak Street Health, Inc., together with its subsidiaries, offers healthcare services to the patients in the United States. The company operates primary care centers for Medicare beneficiaries. As of December 31, 2020, it operated 79 centers in Illinois, Indiana, Michigan, Mississippi, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee, and Texas. The company was founded in 2012 and is headquartered in Chicago, Illinois.
Universal Health Services logo

#100 - Universal Health Services

NYSE:UHS
Stock Price: $135.62 (-$1.73)
PE Ratio: 10.73
Market Cap: $11.27 billion
P/E Ratio: 10.7
Dividend Yield: 0.59 %
Consensus Rating: Hold (7 Buy Ratings, 3 Hold Ratings, 5 Sell Ratings)
Consensus Price Target: $155.71 (14.8% Upside)
Universal Health Services, Inc. operates as a healthcare management company, which through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, and outpatient facilities. It operates through the following segments: Acute Care Hospital Services, Behavioral Health Care Services, and Other. The Other segment consists of centralized services such as information technology, purchasing, reimbursement, accounting and finance, taxation, legal, advertising, and design and construction. The company was founded by Alan B. Miller in 1979 and is headquartered in King of Prussia, PA.

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.